Publication: Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease
Issued Date
2018-05-01
Resource Type
ISSN
22121102
22121099
22121099
Other identifier(s)
2-s2.0-85046802610
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Value in Health Regional Issues. Vol.15, (2018), 155-160
Suggested Citation
Oraluck Pattanaprateep, Atiporn Ingsathit, Mark McEvoy, John Attia, Ammarin Thakkinstian Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease. Value in Health Regional Issues. Vol.15, (2018), 155-160. doi:10.1016/j.vhri.2017.12.011 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45759
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease
Abstract
© 2018 Objectives: To assess the cost effectiveness of renin-angiotensin aldosterone system (RAAS) blockade in the progression of chronic kidney disease using Thai clinical data in 2014. Methods: A Markov model for cost-effectiveness analysis was applied to estimate from a societal perspective the cost per quality-adjusted life-year (QALY) gained and the incremental cost-effectiveness ratio of RAAS versus non-RAAS used in preventing the progression of end-stage renal disease and death stratified by diabetic and nondiabetic patients. Input parameters related to clinical outcomes were obtained from a cohort study of treatment effectiveness, whereas costs were retrieved from the Ramathibodi Hospital electronic database in 2015 and the Health Intervention and Technology Assessment Program in Thailand. One-way analysis and probabilistic sensitivity analysis were performed to evaluate uncertainty surrounding model parameters. Results: From the model, using RAAS improved QALY from 2.41 to 3.16 years and from 2.37 to 3.20 years in diabetic and nondiabetic groups, respectively. The incremental cost-effectiveness ratios for these groups were 78,250 baht (US $2,353.39) and 66,674 baht (US $2,005.22), respectively. Conclusions: Using RAAS in patients with chronic kidney disease improved QALY in both diabetic and nondiabetic patients and proved to be cost-effective.